Squarepoint
PFE icon

Squarepoint’s Pfizer PFE Stock Holding History

Squarepoint’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.24M Sell
293,400
-281,400
-49% -$7.49M 0.01% 1183
2025
Q4 		$14.3M Sell
574,800
-1,390,900
-71% -$35.1M 0.02% 902
2025
Q3 		$50.1M Sell
1,965,700
-2,879,700
-59% -$71.1M 0.05% 406
2025
Q2 		$117M Buy
4,845,400
+3,899,000
+412% +$90.9M 0.12% 171
2025
Q1 		$24M Buy
946,400
+737,700
+353% +$19.3M 0.03% 602
2024
Q4 		$5.54M Sell
208,700
-407,400
-66% -$11.1M 0.01% 1555
2024
Q3 		$17.8M Buy
616,100
+241,900
+65% +$7.06M 0.03% 642
2024
Q2 		$10.5M Sell
374,200
-917,900
-71% -$25.3M 0.02% 921
2024
Q1 		$35.9M Buy
1,292,100
+945,700
+273% +$26.2M 0.06% 368
2023
Q4 		$9.97M Sell
346,400
-823,600
-70% -$24.9M 0.02% 956
2023
Q3 		$38.8M Buy
1,170,000
+447,200
+62% +$15.8M 0.1% 232
2023
Q2 		$26.5M Buy
722,800
+250,200
+53% +$9.74M 0.08% 276
2023
Q1 		$19.3M Sell
472,600
-219,900
-32% -$9.5M 0.08% 282
2022
Q4 		$35.5M Buy
692,500
+10,500
+2% +$503K 0.14% 142
2022
Q3 		$29.8M Sell
682,000
-89,400
-12% -$4.34M 0.15% 133
2022
Q2 		$40.4M Buy
771,400
+34,300
+5% +$1.75M 0.23% 77
2022
Q1 		$38.2M Buy
737,100
+173,500
+31% +$9M 0.16% 124
2021
Q4 		$33.3M Sell
563,600
-19,700
-3% -$976K 0.09% 198
2021
Q3 		$25.1M Sell
583,300
-52,400
-8% -$2.32M 0.07% 248
2021
Q2 		$24.9M Buy
635,700
+459,700
+261% +$17.9M 0.09% 197
2021
Q1 		$6.38M Buy
176,000
+170,400
+3,043% +$6.05M 0.04% 528
2020
Q4 		$206K Sell
5,600
-3,148
-36% -$115K ﹤0.01% 2489
2020
Q3 		$305K Hold
8,748
– – ﹤0.01% 1786
2020
Q2 		$271K Buy
+8,748
New +$297K ﹤0.01% 1665
2020
Q1 		– Sell
-12,121
Closed -$451K – 2355
2019
Q4 		$451K Sell
12,121
-6,956
-36% -$248K ﹤0.01% 1826
2019
Q3 		$650K Buy
19,077
+4,953
+35% +$180K 0.01% 1481
2019
Q2 		$580K Buy
14,124
+633
+5% +$25.1K 0.01% 1577
2019
Q1 		$544K Buy
+13,491
New +$540K 0.01% 1446

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Squarepoint's PFE Position: Q1 2026 in Review

Squarepoint reduced its Pfizer (PFE) stake by 44% in Q1 2026, selling an estimated $113M and leaving 5,433,651 shares worth $153M. The position accounts for 0.18% of the portfolio, ranked #86.

Squarepoint first reported a position in PFE in Q1 2015 and has held it in 41 quarters since. The position peaked at $262M in Q3 2025. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Squarepoint held 5,433,651 shares of Pfizer worth $153M as of Q1 2026.
  • Squarepoint sold 4,249,615 Pfizer shares in Q1 2026, an estimated $113M.
  • Pfizer made up 0.18% of Squarepoint's portfolio in Q1 2026, its #86 holding.
  • Squarepoint first reported a position in Pfizer in Q1 2015 and has held it in 41 quarters since.
  • Squarepoint's Pfizer position peaked at $262M in Q3 2025.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.